



HFS

Illinois Department of
Healthcare and Family Services

JB Pritzker, Governor
Elizabeth M. Whitehorn, Director

201 South Grand Avenue East, Springfield, Illinois 62763
Telephone: +1 217-782-1200, TTY: +1 800-526-5812

**Illinois Drug Utilization Review
Board Meeting Minutes
January 25, 2024**

I. Call to Order, Roll Call

- a. Call to order
 - i. Meeting conducted via a Webex webinar format.
 - ii. The meeting was recorded in accordance with the Open Meetings Act. Guests wishing to speak during public comment were requested to type name and affiliation in the Webex Chat. Phone-in attendees instructed to email Jen DeWitt with full name, title, and affiliation.
 - iii. Dr. Stevens called the meeting to order at 8:30am.
- b. Roll call
 - i. Roll call was taken and a quorum was established. Present: Drs. Stevens, Schriever, Ahluwalia, An, Aziz, Nikocecic, Sreedhar, Wheat.

II. Agenda, conflict of interest review, and approval of October 26, 2023 meeting minutes

- a. No DUR Board members had conflicts of interest pertinent to the agenda. Dr. Stevens reminded DUR Board members to recuse themselves from discussion if conflicts of interest are present and to provide an updated *Conflict of Interest* form if new conflicts arise.
- b. January 25, 2024 meeting agenda and October 26, 2023 meeting minutes- No changes or additions. Motion to approve both made by Dr. Schriever, seconded by Dr. An.
- c. Vote: In favor- 8; Against- 0; Abstentions- 0. October 26, 2023 meeting minutes approved.

III. Board Updates

- a. Dr. Erica Stevens is the DUR Board's 2024 Chairperson and Dr. Christopher Schriever is the Board's 2024 Vice-chairperson.
- b. Dr. Santana Wheat was introduced.
- c. Board member annual training. All Board members have completed their 2023 modules. The 2024 modules are on the OneNet website. Completion deadline is 12/31/2024.

IV. Introduction of new DUR Bylaws Discussion

- a. Changes to current Bylaws draft:
 - i. Motion made by Dr. Sreedhar to remove point "D" from Article II, Section I. Article II, Section I, point "D" states that the "Three (3) ex-officio members will count towards a quorum, be able to speak on agenda items, but will not be able to make motions, second a motion, or cast a vote on issues before the Board." Seconded by Dr. An.
 - ii. Vote: In favor- 8; Against- 0; Abstentions- 0. Point "D" from Article II, Section I will be removed from the Bylaws.
 - iii. Motion made by Dr. Sreedhar to approve the draft Bylaws, seconded by Dr. An.
 - iv. Vote: In favor- 8; Against- 0; Abstentions- 0. Draft Bylaws approved.

V. Quarterly Reports – presented by Maurice Shaw, PharmD

- a. Top 10 spend Fee-For-Service (FFS) drugs (2023Q4)
- b. Top 10 script count FFS- Prescription only (2023Q4)
- c. Top 10 script count FFS- OTC only (2023Q4)

- d. Top 5 script count by disease state: Diabetes (FFS and Managed Care Organization (MCO), 2023Q3)
 - i. Dr. Shaw presented on inappropriate glipizide prescribing as requested by the Board.
 - ii. Participants on glipizide were analyzed to see if they were also receiving a first-line medication for T2DM, specifically a SGLT-2 inhibitor or a GLP-1 receptor agonist.
 - iii. Out of 3,215 scripts, there were 2,702 participants. Only 35% of participants taking glipizide were on either a SGLT-2 inhibitor or a GLP-1 receptor agonist.
 - iv. Board requested a further investigation into glipizide prescribing, which included the age range for the participants.
- e. Top 5 script count by disease state: Hypertension (FFS and MCO, 2023Q3)
 - i. Prazosin and hydralazine breakdown
 - a. Prazosin: Majority of participants had no hypertension diagnosis.
 - b. Hydralazine: Majority of participants did have a hypertension diagnosis.
 - ii. The Board requested to research the percentage of participants on hydralazine who had a heart failure diagnosis, chronic kidney disease diagnosis or end-stage renal disease diagnosis for the next meeting.
- f. Top 5 script count by disease state: Depression (FFS and MCO, 2023Q3)
- g. Top 5 script count by disease state: Asthma (FFS and MCO, 2023Q3)

VI. Retrospective DUR – presented by Christina Petrykiw, PharmD, CDCES

- a. RetroDUR 300
 - i. Study 36 had 99 FFS participants and 92 TPL participants with 1020 RetroDUR issues. Pharmacist profile review identified 148 additional issues.
 - ii. Study 37 had 89 FFS participants and 112 TPL participants with 1074 RetroDUR issues. Pharmacist profile review identified 299 additional issues.
 - iii. Study 36: Issues warranting outreach
 - a. Daily dose issues= 892
 - b. Duplicate therapy= 99
 - c. Drug interaction= 11
 - d. Inappropriate therapy= 18
 - e. Pharmacist identified= 24 participants with 59 issues
 - iv. Study 37: Issues warranting outreach
 - a. Daily dose issues= 940
 - b. Duplicate therapy= 114
 - c. Drug interaction= 7
 - d. Inappropriate therapy= 13
 - e. Pharmacist identified= 85 participants with 148 issues
 - v. Study 36 Outcomes
 - a. Calls/recommendations made= 24, faxes sent (issue, pain program, benzodiazepine, asthma, vitamin D)= 1, participants will be reevaluated= 2, recommended for narcotic edit= 1
 - vi. Study 37 Outcomes
 - a. Calls/recommendations made= 34, faxes sent= 23, participants will be reevaluated= 5, insurance/eligibility/provider change= 1
 - vii. Discussion
 - a. Board recommended reviewing the extent of concomitant H2-blocker and proton pump inhibitor use since there is not a benefit to taking both.
 - b. Motion to look further into the utilization of vitamin D 50,000 units made by Dr. Sreedhar, seconded by Dr. An.
 - viii. Vote: In favor- 8; Against- 0; Abstentions- 0. Motion approved.

VII. Prospective DUR – Presented by Christina Petrykiw, PharmD, CDCES

- a. Available prospective DUR tools
 - i. Prospective screening
 - ii. Edits (including quantity, maximum or minimum daily dose, duplicate therapy, gender, age, drug interactions, disease state confirmations, opioid-related safety edits)

- iii. Step therapy
- iv. Prior authorization
- v. Narcotic edit, restricted recipient program/lock-ins
- b. Educational tools
 - i. Patient-specific and/or drug specific issues.
 - ii. Academic Detailing
 - iii. Intensified review or monitoring of selected prescribers or dispensers.

VIII. Public Comments – No public comments were made.

IX. Department Updates – Arvind Goyal, MD
 a. New HFS Director as of 1/1/2024: Elizabeth (Lizzie) Whitehorn.

X. Adjournment
 a. Next DUR Board Meeting- Thursday, April 25, 2024, 8:30am – 10:30am
 b. Motion made to adjourn the meeting at 10:21am by Dr. Aziz. Seconded by Dr. Nikocevic.
 c. Vote: In favor- 8; Against- 0; Abstentions- 0. Meeting adjourned.

Meeting Attendance

DUR Board Members

Erica Stevens, PharmD, BCGP, Chair
 Christopher Schriever, PharmD, MS, AAHVP, Vice-Chair
 Aneet Ahluwalia, MD
 Sam An, PharmD
 Ihab Aziz, MD, ABFM, FAAFP
 Bedrija Nikocevic, PharmD, BCACP
 Radhika Sreedhar, MD, MS, FACP
 Santana Wheat, MD, MPH, FAAFP, AAHIVS

Staff/Panelists

Donna Clay, BSPHarm – UIC
 Claudia Colombo, PharmD – UIC Springfield
 Melissa Davis – BPAS
 Jen DeWitt, BSPHarm – UIC Springfield
 Sheri Dolan, BSPHarm – UIC Springfield
 Thomas Dorn, PharmD – UIC
 Heather Freeman – BPAS
 Arvind Goyal, MD, MPH, MBA - Medical Director, HFS
 Jose Jimenez, Bureau Chief – BPAS
 Debra Long – BPAS
 Mary Moody, BSPHarm – UIC
 Christina Petrykiw, PharmD, CDCES – UIC
 Maurice Shaw, PharmD – UIC Springfield

Guests/Attendees

Kimbra Brooks
 Gary Dougherty
 Brielle Dozier
 Kevin Hall
 Kelly Hamilton
 Janie Huff
 Clemice Hurst
 Doug Johnson

Patrick Lindstrom
Phil Lohec
Huzefa Master
A Meizlik
Nichole Palusinski
Kelly Petrowski
Heather Pezewski
Gary Parenteau
Kenneth Ring
Ken Ryan
Thomas Vayalil
Jon Vlasnik
Chase Williams
Call-in User (630544****)

Approved April 25, 2024 by the Illinois Drug Utilization Review Board